NCT01037127View on ClinicalTrials.gov

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

January 31, 2013

Conditions
Cancer
Interventions
DRUG

GSK1120212

Daily oral dosing

Trial Locations (10)

2145

GSK Investigational Site, Westmead

3002

GSK Investigational Site, East Melbourne

6009

GSK Investigational Site, Nedlands

10016

GSK Investigational Site, New York

19104

GSK Investigational Site, Philadelphia

37203

GSK Investigational Site, Nashville

80045

GSK Investigational Site, Aurora

90024

GSK Investigational Site, Los Angeles

37232-6307

GSK Investigational Site, Nashville

77030-4009

GSK Investigational Site, Houston

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01037127 - Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor | Biotech Hunter | Biotech Hunter